Ey e s O N T H E F U T U R EY E A R O N E I N R E V I E W F R O M T H E R E S E A R C H E R S AT T H E i C A P T U R4 E C E N T R E / M R L

2 0 0 0 – 2 0 0 1

S T R A T E G I C G O A L STo conduct and publish international-qualityresearch.To become the most sought-after destination for trainees and scientists committed to theelimination of heart, lung, and blood vessel disease.To earn the respect of our clinical peers for our role in health sciences, health education,and health care.

We pursue our mission through several interrelated avenues:

Research

Providing a stimulating environment that attracts and retains world-class researchers;Obtaining timely and accessible results with highimpact;Conducting multidisciplinary research into causes, mechanisms and cures for heart, lung,and blood vessel diseases, with a commitmentto better management and prevention;Developing effective and timely solutions to diverse scientific problems;Integrating basic and clinical research;Creating synergistic ties with investigators and teams locally, regionally, nationally andinternationally;Adhering to the highest ethical standards;

Innovation

Using innovative discovery processes to relievehuman suffering and achieve the best possiblequality of life for people with existing (or riskof ) heart, lung, and blood vessel diseases;Leading in the application of state-of-the-arttechnology;Fostering a supportive, stimulating environmentthat will allow the creativity necessary to furtherour understanding of these disorders;

Communication and Education

Communicating timely and stimulating infor-mation to the public regarding relevant and significant developments and discoveries;Educating and training students and researcherswithin an environment of endless determinationand enthusiasm for the process of discovery and learning;

Sustainabil i ty

Creating a sustainable research environment withpotential to grow and evolve; andAppreciating and using effectively public, private,and corporate resources devoted to the Centre.

M I S S I O N , V I S I O N & V A L U E S

Pu r s u i n g e x c e l l e n c eby using creativity and advanced technology,the icaptur4e Centre team formulates, designs, executes, analyzes,

synthesizes, and reports experimental findings regarding the causes,

mechanisms, outcomes and implications of heart, lung, and blood vessel diseases. Our

values of achievement, efficiency, equality, respect and integrity underlie our quest to be

the world leader in understanding and eliminating heart, lung and blood vessel disorders.

•

•

•

i C A P T U R 4 E C E N T R E / M R L

•

•

•

•

•

•

•

•

•

•

•

•

•

•

At Providence Health Care, we are passionate about the highest qualitypatient care for all of our patients,and we are sensitive to the needs offamilies whose members are ill or atrisk. We are equally dedicated toadvancing the boundaries of knowl-edge through scientific research anddiscovery in order to improve ourcare. Heart, lung, and blood vesseldiseases play an overwhelmingly dom-inant role in death, and long-term ill-ness and disability for Canadians. Ourhealth care organization plays a lead-ership role in British Columbia in thecare of patients and families affectedby heart, lung, and blood vessel diseases, and in research about

such conditions. We are especiallycommitted to a better understandingof asthma, lung disease related to air pollution, smoking and viruses,hardening of the arteries, heart valve disease, heart failure leading to transplantation, and heart risks like high blood fats.

New boundaries of knowledge will be established through the perse-verance, dedication, creativity andsynergy of our teams of scientists,technologists, and collaborating healthcare professionals who are focused on devastating heart and lung condi-tions. At our St. Paul’s Hospital site,the iCAPTUR4E Centre /MRL is makinggreat strides towards innovative

solutions in order to speed advancesin patient care. Providence Health Care enthusiastically embraces theoutstanding individuals in the Centreas they continue their quest foranswers to some of the toughestquestions in science and medicine.

It is with great pleasure that I offermy kindest regards for continuing success and research advancements in this upcoming year.

CARL ROY

President and CEOProvidence Health Care

The innovative research being produced by the iCAPTUR4ECentre /MRL team in conjunctionwith Providence Health Care, is of the utmost importance in the searchfor the sources of heart, lung, andblood vessel diseases. Thanks to this outstanding group of researchers,we are closer than ever before to an understanding of the link betweengenes and the environment, and to identifying the causes of a set of painful and costly diseases.

The UBC researchers and their

colleagues who are engaged in thisexciting investigation have alreadygained widespread recognition, andtheir success is testimony to the valueof collaboration across disciplines andinstitutions. Through the teamwork of dedicated men and women in hos-pitals and laboratories in BritishColumbia, we shall find innovativesolutions to the problems of heartand lung disease, and turn scientificdiscoveries into effective tools to combat illness around the world.

All of us at UBC are proud to be

associated with the iCAPTUR4ECentre /MRL and its partners, and aregrateful for their truly groundbreakingresearch. We look forward to theirongoing contributions to the advance-ment of scientific and medical knowl-edge in this most challenging field.

MARTHA C . P IPER

PresidentUniversity of British Columbia

Understanding diseases of the heart,lung and blood vessels remains a priority for many of us at ProvidenceHealth Care as cardiovascular diseaseaccounts for the death of moreCanadians each year than any otherdisease. Lung diseases including asthma and chronic obstruction ofairways are also major contributionsto the burden of Canadian illness.

Thirty-six per cent of all male deaths in Canada in 1995 (the latestavailable statistics) were due to heart diseases, diseases of the bloodvessels and stroke. For women, thetoll was even higher—39 per cent of all female deaths in 1995 were due to cardiovascular disease. And,

cardiovascular diseases cost theCanadian economy over $18 billion ayear according to a 1994 study by theHeart and Stroke Foundation. Today, it is even higher.

The men and women conductingresearch at the iCAPTUR4E Centre /MRLare well aware of these statistics. Butthey are even more keenly aware ofthe patients at Providence Health Carewho look to them for answers to thecomplex question of how to treat theircardiovascular and respiratory diseaseand make them well again.

The $17 million the iCAPTURE teamreceived in the extremely competitiveCanada Foundation for Innovation competition is a testament to their

talent, their ingenuity, and their abilityto peer into the future and say “wecan do that.” The future didn’t justarrive at Providence Health Care. It wascourted, planned, dreamed about, and thanks to the folks at iCAPTUR4ECentre /MRL and all of their many partners and supporters, it wasachieved. Congratulations to everyonefor a busy and productive first year.

MICHAEL V. O’SHAUGHNESSY, OBC, PhD

Vice-President, ResearchProvidence Health Care

“The future is not a gift — it is an achievement.”H a r r y L a u d e r , 1 8 7 0 - 1 9 5 0

The allocation of new funds nationally and regionally has allowed Canadian scientists and their

trainees to move more briskly, to think more concretely about their goals, and to access breath-

taking technologies relevant to the frontiers of health research. Among the many avenues of

scientific investigation, none are more compelling to us than the links between gene variation,

gene regulation, and gene expression, and our physiological makeup. In disparate disciplines

and realms of investigation—from basic laboratories to clinics and hospital wards to communi-

ties—there has emerged a reliance on images to define and refine both genotype (the

genetic identity of an individual, not shown as an outward characteristic) and phenotype

(visible characteristics such as hair colour, weight, or the presence or absence of a disease).

The development of the iCAPTUR4E Centre /MRL reflects the virtues and values of applying a

range of new and emerging imaging technologies to pressing questions about our genetic

makeup and the way in which the environment affects us. With this new technological infra-

structure, the innovative investigators in the Centre will provide leadership in imaging, cell

analysis, and phenotyping in order to dissect the mysteries of heart, lung and blood vessel

disease. Through our imaging technologies, we are “eyeing the future,” and setting lofty goals

that include improving and saving lives.

July 26, 2000....A day of wonder, celebration, and uncontainable excitement. This was the

day the Canada Foundation for Innovation application from our team was approved and our

$17 million grant awarded. With this momentous announcement, prospects for life saving

research into the causes and solutions for heart, lung, and blood vessel disease advanced

dramatically at Providence Health Care and the University of British Columbia. This award

represents a major expansion to our current laboratories, a major upgrade to our available

M E S S A G E F R O M T H E D I R E C T O R S

Scientif ic discoveryprovides the foundations on which innovation

in health maintenance and intervention can be

built. Canada is in the midst of a renaissance

in many domains of research and discovery.

technology, and a boost to our capacity for innovation. Thanks to the generous support of our

inaugural funding partners—the Canada Foundation for Innovation, British Columbia Knowledge

Development Fund (applied for), Providence Health Care, the University of British Columbia, the

Heart and Stroke Foundation of BC and Yukon, the BC Lung Association, and many vendors

including IBM—we have been successful in the first step of our dream. Fourteen months of

joyful teamwork since the award have allowed us to bring the preliminary phase of our dream

to life. We have intensified our research efforts, are actively recruiting new staff and faculty,

successfully launched our new website (www.icapture.ca), and are fielding calls from scientists,

prospective trainees, vendors, media, and the general public about the Centre. The architectural

blueprints of the new space are drawn, mapping out our deeply needed facility.

We have many steps ahead in implementation, but we are eagerly pressing forward in antici-

pation of the full and effective operation of the new tools and technologies. The day-to-day

advances now occurring in the Centre reflect the tireless and collegial work of all involved. We

want to thank everyone for the extra hours and renewed commitment that have been funnelled

into this project in order to assure the iCAPTUR4E Centre /MRL achieves its goal of becoming

an internationally unique research facility, renowned for excellence in imaging, and in cardiovas-

cular and respiratory research and training. While our relentless inquiry will undoubtedly benefit

the many patients within the walls of Providence Health Care facilities and the immediate com-

munities we serve, we know it will also benefit those with heart, lung and blood vessel dis-

eases around the world. Congratulations to all on a productive, creative, and intense first year.

With warm regards,

Peter Paré

Bruce McManus

P E T E R P A R É B R U C E M C M A N U S

D I R E C T O R

D I R E C T O R

MRL becomes The iC APTUR 4E Centre / MRL

Although the announcement that the iCAPTUR4E Centrefunding from the Canada Foundation for Innovation (CFI)was not received until mid-2000, the origins of this initia-tive go back a long way. The iCAPTUR4E Centre builds onthe 23-year history of the Pulmonary Research Laboratory,which, in the mid-1990’s amalgamated with the Cardio-vascular Research Laboratory and the AtherosclerosisSpecialty Laboratory to become the McDonald ResearchLaboratories (MRL). The iCAPTUR4E Centre / MRL is theresulting entity, an enterprise complete with a track recordand a rich history, but reinvigorated by the infusion of anew scientific strategy based on four distinct foci (cores)and a new source of funding.

Our Home at St. Paul’s Hospital

With the completion of the Human Genome Project and the entire three billion base-pair sequence of a singlehuman subject revealed, the next challenge for biomedicalresearch is to discover inter-individual variations in thegenetic code and how they interact with the environmentto produce disease phenotypes. At present the iCAPTUR4ECentre /MRL has over 160 personnel working towardsunderstanding the genetic links between our environmentand diseases of the heart, lung, and blood vessels.

Much of the research we do here relies on our uniqueregistries of tissue from patients who have a variety ofheart, lung, and blood vessel diseases. These patientscome to St. Paul’s Hospital to receive life-saving treatmentand often, after these surgeries or procedures, will agreeto provide a sample of this removed tissue to the tissuebank. The infusion of our new imaging technology willbe used to investigate disease features at different levels; in the genes, in the proteins that are made from thegenes, in tissue, in organs from which samples of tissueare taken, and, finally, within patients themselves. Similarapproaches will be used to investigate how heart and lungdisease is expressed in special features of animal and cellmodels that mimic human diseases. Ultimately, we mustunderstand human diseases, and thus studies of humantissues become essential.

The Cores

We have organized our research pursuits into four sections,or “cores.”

CORE 1 Molecular PhenotypingThe aim of the Molecular Phenotyping Core is to charac-terize and quantify RNA, DNA, and protein expression inhuman and animal tissues and cells. These expression patterns of genes, especially when measured and relatedto structure and dynamic events in tissues, organs, andpeople will suggest new ways to prevent, treat or cure diseases. The ultimate goal is to provide answers tohypotheses at a molecular level.

CORE 2 Ultrastructural ImagingAssessing the fine structural detail of tissues, cells, andmolecules is a crucial component of an advanced imagingcentre. The increased resolution of the TransmissionElectron Microscope (TEM) is essential to observe specificmolecules in cells. TEM allows molecules to be visualizedat powers that range from 10 to 100,000-fold magnification.The Atomic Force Microscope (AFM) will permit imaging oflive specimens in motion, thus augmenting and comple-menting the TEM. The synergistic and high-resolution infor-mation generated from both tools is critical to clarifying thedetails of adverse processes in heart and lung diseases.

CORE 3 Dynamic Cel lular Imaging and BiophysicsA crucial goal for iCAPTUR4E is to examine events within asingle living cell as they happen. Imaging of moleculeswithin a cell and measurement of the cell’s electrical activi-ty can be accomplished with Simultaneous Imaging andElectrophysiology. Images captured in two dimensionsdeep in tissues can be reconstructed in 3D and analyzedboth spatially and for molecular dynamics. These technolo-gies provide dramatic real-time, high resolution images and records of normal and abnormal events. These tech-niques complement other levels of phenotyping proposedby the iCAPTUR4E Centre in collaboration with molecularand genomic partners.

CORE 4 Organ Pathophysiology and ImagingThe ultimate goal of iCAPTUR4E is to use informationgained about whole organs and organisms to assist peopleliving with heart, lung, and blood vessel diseases. For thisreason, organ structure and function will be assessed inpatients and in living, working organs using ultrasound,hemodynamic monitoring, magnetic resonance imaging(MRI), and computed tomography (CT) scanning technology.

Year One Groundwork

Our first year as iCAPTUR4E Centre /MRL was packed withplanning, planning, and more planning. Planning space,planning education initiatives, planning the purchase oftechnology, and planning how to let people know about us.

SpaceAs a part of the successful CFI application, the Providenceboard identified 20,000 square feet of additional researchand educational space to support iCAPTUR4E Centre /MRL’swork. Preliminary space plans were drawn up by LindenArchitecture Studios. The plans were modified based onfeedback from iCAPTUR4E Centre /MRL personnel at thebenches and in the offices. The firm of Chernoff Thompsonhas been selected for their architectural services to contin-ue the intensive planning for this project. We have alsoselected the firms of Versacon as mechanical consultantsand RFA as electrical consultants for this project. We havecompleted schematic design planning and are finalizingoptions for laboratory fixtures and fittings.

O U R I N A U G U R A L Y E A R I N R E V I E W : 2 0 0 0 – 2 0 0 1 *

* September 2000 – September 2001

Education and TrainingOver the past year, we have clarified our goals for enrich-ing the entire training program. This will include additionaleducational courses and seminars on all new equipment,industry exchanges, QA / QC , and consistent documentationprocedures. We will be developing additional training ini-tiatives to support a proposal for the recently announcedCIHR Training Program for Cardiovascular, Pulmonary,Blood, and Critical Care Research. This is an excellentopportunity for the iCAPTUR4E Centre /MRL to be a part of a world class multi-institutional training plan based out of the Vancouver area. Additionally, our extraordinaryiCAPTUR4E Summer Student Research Day on August 17th,2001 was an outstanding success, building on years ofMRL student research programs. Many thanks to the Heartand Stroke Foundation of BC and Yukon and the BC LungAssociation for supporting student research.

TechnologyIBM was the first vendor selected to partner withiCAPTUR4E and will provide network and computerequipment. We have placed our first order with IBM fornew computer technology. Also, during 2000-01, manyvendors made presentations about their imaging technol-ogy at in-house seminars for evaluation by staff. Furtherpurchasing decisions will be made as our laboratoryspace comes together.

CommunicationsIn the early part of 2001, we hired a communications consultant specializing in health research to develop an18-month communications strategy. The goal was to getthe word out about iCAPTUR4E Centre /MRL. This plan wascompleted in May and implementation began over thesummer. Using this plan, we are actively seeking collabo-rators, new recruits, and generally trying to let interestedaudiences know that we’re here and we’re functioning. We will be using email and Internet technology wheneverpossible to keep everyone apprised of our progress.

Newsletters, this annual review, and targeted media stories are also part of the plan.

In the summer of 2001, we also held an internal compe-tition to create a logo to help people recognize our work.We then developed a comprehensive web site to get ourstory and our images onto the Internet. “www.icapture.ca”was unveiled in September to present an internationalaudience with our hopes, dreams and ambitions.

O U R N E W L O G O :

The Future

“Any sufficiently advanced technology

is indistinguishable from magic.”— A R T H U R C . C L A R K E

Our goals over the next few years are not modest; theyare complex, challenging, and ambitious. We do not wantto rest within the boundaries of what science currentlyviews as possible. Our goals include pushing those bound-aries—past the possible, into the seemingly magical. Weoften use the word “cure” when we talk about impactingheart, lung and blood vessel diseases. We do not want tolimit ourselves by only using words like “alleviating” or“improving.” We’re seeking to find a cure for diseases thatcut productive and happy lives short. Just like our col-leagues on the wards and in the clinics, we’re here to savelives and return patients to their work and their families.

The iCAPTUR4E Centre / MRL investigators have already improved patient health by:

• Demonstrating direct viral injury of heart muscle cells, changing the current approach to therapy;

• Discovering excess fat in arteries of patients shortly after heart transplantation, resulting in a new practice of post-op

intensive lipid therapy;

• Demonstrating how airways narrow due to asthma, sparking dramatic alterations in asthma therapy world-wide;

• Showing that lungs infected with adenovirus are more likely to develop COPD, providing a new target for potential

intervention;

• Definition of leukocyte kinetics in sepsis, trauma and pollutant inhalation, creating a new paradigm in pathogenesis;

• Developing novel algorithms to measure emphysema using CT scanning; and

• Elucidating changes in fat and carbohydrate metabolism in ischemic and hypertrophied hearts.

MICHAE L F. A L L ARD , B S c , MD , F RCPC is an Investigator atthe University of British Columbia’s iCAPTUR4E Centre / MRL atthe St. Paul’s Hospital site. Dr. Allard’s research examines howthe heart uses fuels such as sugar for energy production, howhormones and diseases alter this fuel-use and how alterationsin fuel-use contribute to heart dysfunction. In the next threeyears, he will focus on understanding the specific subcellularmechanisms responsible for the alterations in fuel use by dis-eased hearts, specifically hearts enlarged by long-standing pres-sure overload. Ultimately, he hopes to develop novel therapeuticapproaches to modulate fuel-use by the heart and, thereby,improve heart function.

TONY BA I , MD , F RCPC is an Investigator with the iCAPTUR4E

Centre / MRL who trained in Internal Medicine, Physiology,Pharmacology and Respiratory Medicine at the University ofOtago in Dunedin, New Zealand, St. Thomas’s Hospital inLondon, England, and McGill University. For more than twodecades, he has studied the underlying mechanisms and causesof asthma and he is now investigating the determinants of asth-ma severity and the role of interactions between the immunesystem and airway innervation in the expression of the inflam-matory response in the lung. Specifically, he is interested in the interaction of the IL-6 family of cytokines with neuro-trans-mitters, nerves and smooth muscle, the use of non-invasive biomarkers of asthma control and a new therapy for idiopathicpulmonary fibrosis. He collaborates with other members in thepulmonary research group as well as investigators from the UBC Faculty of Pharmaceutical Sciences and Dr. D. Knight at the University of Western Australia.

DE L DORSCHE I D , PhD , MD , F RCPC joined the iCAPTUR4E

Centre / MRL in July 2000, after being recruited from theUniversity of Chicago. The physician-scientist serves as an inten-sivist in the ICU at St. Paul’s Hospital and leads a researchgroup investigating the role of the airway epithelium in the genesis of inflammatory airways diseases. Dr. Dorscheid is nowstudying the role of glucocorticoid-induced airway epithelial cellapoptosis, novel glycoproteins involved in the repair of injuredepithelium and the expression of Fas ligand as an immune barrier for the airway in changes associated with chronic airwaysremodeling.

J I R I F ROHL I CH , MD , F RCPC is the academic director of the St. Paul’s Hospital Healthy Heart Program where he conductsand oversees both basic and clinical research. Dr. Frohlich’s spe-cialty is medical biochemistry, a subspecialty of pathology andlaboratory medicine. Over the last 25 years, he has extendedhis specialty into laboratory and clinical aspects of lipoproteinmetabolism and atherosclerosis. He now studies dyslipidemias,atherosclerosis, phytosterols in medicine, genetic determinantsof response to inflammation and atherosclerosis and HDLmetabolism.

SH I ZU HAYASH I , PhD a molecular biologist in the iCAPTUR4E

Centre / MRL, trained with Dr. David Suzuki in the Department ofBiochemistry at UBC and at the University of Konstanz, Germany.Dr. Hayashi works closely with Drs. James Hogg, Stephan vanEeden and Andrew Sandford in studying the role of adenovirusE1A in the pathogenesis of chronic obstructive pulmonary dis-ease. She also collaborates with Dr. William MacNee, Universityof Edinburgh, and Dr. Ralph Brattsand, AstraZeneca R&D, Lund,Sweden.

R I CHARD G . H EG E L E , PhD , MD , F RCPC , is an investigator in the iCAPTUR4E Centre / MRL at St. Paul’s Hospital and ananatomical pathologist at St. Paul’s. Dr. Hegele is studying therole of respiratory viral infections in the onset of childhoodasthma and allergy, molecular viral diagnosis and animal modelsof viral lung infections. Over the next few years he will focus onexamining effects of interventions designed to prevent post-bronchiolitis asthma and allergy in children. He collaboratesextensively with other UBC scientists as well as with Dr.Giovanni Piedimonte at the University of Miami and Dr. BrunoBattistini at Université Laval, Quebec.

J OHN H I L L , BMLS c , MS c , PhD directs the AtherosclerosisSpecialty Laboratory at St. Paul’s Hospital, studying lipids andlipoproteins and their relationship with coronary artery disease.Specifically, Dr. Hill’s research has focused on the structure-func-tion relationships of lipolytic enzymes that influence the levelsof circulating HDL cholesterol. In the next few years the focus of his research will expand to include the analysis of geneticmarkers related to the development of coronary artery diseasewithin a variety of patient populations.

Investigator Biosi C A P T U R 4 E C E N T R E / M R L

J AMES HOGG , PhD , MD , F R S C is Professor Emeritus ofPathology at UBC and an investigator in the iCAPTUR4E Centre /MRL. Dr. Hogg’s research focusses on the inflammatory process inthe lung with particular reference to the structure and function ofthe lungs in Chronic Obstructive Pulmonary Disease. On his retire-ment at the end of 2000, he was honoured by the St. Paul’sHospital Foundation, which established the “Dr. James HoggYoung Scientist Award” in recognition of his leadership and men-torship of many young scientists over a stellar career, including23 years at St. Paul’s.

I S S Y L AHER , PhD a faculty member in Pharmacology andTherapeutics, UBC, specializes in the pharmacology of autoregula-tion, autonomic pharmacology, vascular smooth muscle, and cere-brovascular pharmacology. His interests are in understanding thefunction of small blood vessels in health and disease, in particu-lar how blood vessel diameter is modified on both a short andlong-term basis.

BRUC E MCMANUS , PhD , MD , F RCPC , F C AP, FAC C , F C CP

is co-director of the iCAPTUR4E Centre / MRL, Director of theCardiovascular Research Laboratory and the CardiovascularRegistry and Co-Director of the Vancouver Vascular BiologyResearch Centre. In December 2000, Dr. McManus was alsoappointed scientific director of the Institute of Circulatory andRespiratory Health, one of the Canadian Institutes of HealthResearch. In this capacity, he will lead the development andimplementation of a strategic research plan for Canada toaddress outstanding questions related to cardiac, respiratory,vascular, brain (stroke), blood, and sleep disorders and diseases. His current research centers on host and viral geneticdeterminants of myocardial injury, the molecular mechanisms of myocardial injury in human and animal model myocarditisand in allograft rejection and the role and mechanisms ofendothelial injury in allograft vasculopathy.

PE T ER PAR É , MD is co-director of the iCAPTUR4E Centre / MRL

and the director of the Department and Faculty of MedicineClinical Investigator Programs. Dr. Paré was also the representa-tive for Providence Health Care on the BC Coalition for HealthResearch, the group that was instrumental in the establishmentof the Michael Smith Foundation for Health Research. Hisresearch focusses on the genetics and pathophysiology of asth-ma and chronic obstructive pulmonary disease. He collaborateswith Drs. Bob Schellenberg and Chun Seow in investigating ascheme of events which relate bronchoconstricting stimuli to theultimate airway narrowing that occurs. Dr. Paré also collaborateswith Drs. Sandford, Bai and J. Hogg and with health economistDr. Aslam Anis.

J IM RUSS E L L , MD , F RCPC is an intensivist and internist who did his research training at the University of California, SanFrancisco. Dr. Russell’s research has focused on three areas: trials of new therapy for sepsis (severe infection), septic shockand acute lung injury; hypoxia in the critically ill and exercise-induced hypoxia; and the role of genetics of the inflammatoryresponse in the critically ill. He is now leading a CIHR-fundedmulticentre trial of vasopressin in septic shock, directingresearch at the only Canadian site in the NIH-funded ARDSnet

clinical trial network and preparing to do further training in thegenetics of sepsis. His goal is to link the studies of genetics ofthe inflammatory response to trials of new treatment to deter-mine how a person’s genetic makeup affects response to treat-ment of the critically ill. Dr. Russell collaborates locally with Drs. Keith Walley, Peter Paré and Andrew Sandford and interna-tionally with investigators at Harvard and UCSF.

ANDY SAND FORD , PhD earned a doctorate at Oxford University(1993) with a study of the genetic basis of allergic diseasessuch as asthma. He continues this research at the iCAPTUR4E

Centre / MRL and has broadened his focus, encompassing thegenetic basis to chronic obstructive pulmonary disease. Dr.Sandford now holds a fellowship from the Parker B. FrancisFoundation and has been awarded a Tier 2 Canadian ResearchChair. He collaborates with the MRL’s Dr. Peter Paré and withDrs. Moira Chan-Yeung from UBC and Allan Becker from theUniversity of Manitoba, is studying a cohort of infants at highrisk for developing allergic diseases and evaluating the impor-tance of genetic risk factors for the development of these dis-eases. Dr. Sandford also collaborates with Drs. John Connett of the University of Minnesota and Nicholas Anthonisen of the University of Manitoba in a study of a second cohort ofpatients, which examines the genetic factors that affect the rate of decline of lung function.

ROBER T S CHE L L ENBERG , MD , F RCPC is a scientist at the McDonald Research Laboratories and an Internist /Allergist at St. Paul’s Hospital. Dr. Schellenberg studied at the University ofManitoba and the Johns Hopkins University School of Medicine.His primary interests are asthma and allergic inflammation in themechanisms of excessive airway narrowing of asthmatic tissuesand the modulation of chemotaxis and apoptosis (programmedcell death) of basophils and eosinophils. His other area ofresearch relates to the unique modulation of basophils versuseosinophils in terms of the chemokines inducing migration, theproteases involved in this process, and the cytokines leading toprolonged survival by inhibition of apoptosis. He collaborateswith investigators at UBC and University of Manitoba.

CHUN SEOW, PhD specializes in smooth and skeletal muscle cellphysiology. His research focuses on understanding the structure-function relationship in smooth muscles in general, airwaysmooth muscle in particular. Specifically he studies changes inultrastructure of contractile and cytoskeletal filaments and pro-teins in smooth muscle at different muscle lengths and underphysiological /pathological conditions, and correlates thesechanges to mechanical functions of the cell. His other interestsinclude skeletal muscle mechanics, ATPase cycle associated withthe crossbridge cycle in muscle contraction, energetics of musclecontraction, and mathematical modeling of muscle contraction.

J OHN Y. C . TS ANG , MD , F RCPC is a specialist in Critical CareMedicine and Anaesthesiology and an iCAPTUR4E investigator. He studies endothelins and their antagonists in the patho-genesis of acute pulmonary embolism, and plans to continuestudying endothelin receptor expression in acute pulmonaryembolism.

CORNE L I S ( C AS EY ) VAN BR E EMEN , DVM , MS c , PhD trained as a veterinarian and pharmacologist and was a faculty memberat the University of Miami before returning to Canada to join theMcDonald Research Laboratories. Interested in the control ofblood vessel function in health and disease, Dr. van Breemenuses confocal microscopy combined with measurements of forceand membrane currents and potentials to elucidate the mecha-nisms of intracellular calcium signaling in smooth muscle andendothelial cells. In particular, he is keen to answer two ques-tions: How does one signaling ion, calcium, control a number of separate functions in the same cell; and what are the ionicmechanisms responsible for vascular heterogeneity? He is alsointerested in relating changes in cell signaling in response topathological insults to early functional changes in the develop-ment of vascular disease.

ST EPHAN VAN E ED EN , MD , PhD , F RCPC is a scientist at theiCAPTUR4E Centre / MRL and an Internist at St Paul’s Hospital. Hedid his medical training at the University of Stellenbosch, SouthAfrica, specializing in pulmonology and critical care, and a PhDin Experimental Medicine at UBC. Dr van Eeden’s research dealswith mechanisms of lung inflammation, particularly, lung inflam-mation caused by infection, cigarette smoking and air pollution.His current research addresses the response of bone marrowduring acute and chronic lung inflammation. He has shown thatwhite cells released from bone marrow play a crucial role inlung inflammation caused by cigarette smoke and particulate airpollution. This research has lead to the novel hypothesis thatwhite cells released by the bone marrow are responsible for theincreased rates of heart and lung disease and death in subjectsexposed to high levels of air pollution.

DAV I D WALKER , PhD is a full-time research associate in theiCAPTUR4E Centre / MRL. A graduate of botany and zoology atthe University of California at Santa Barbara and UBC, Dr.Walker’s research encompasses three areas: definition of struc-tural and functional aspects of the migratory pathway of leuko-cytes during inflammatory processes in the lungs and conduct-ing airways; diapedesis to destinations within the interstitiumand the airspaces; and the roles of fibroblasts in this process.His current initiatives include a collaborative study with Dr. Hoggexamining the role of alveolar wall fibroblasts in “normal” andemphysematous human lungs in leukocyte migration. He is alsoworking with Drs. A. Burns and C.W. Smith to examine theprocess of diapedesis across endothelium in vitro and in vivo,and with Professor J. Bert in Chemical Engineering at UBC on astudy of the relationship between fibroblasts and their relation-ship to their extracellular matrix. In collaboration with Dr. BruceMcManus, Dr. Walker is looking at leukocyte interactions withthe endothelium in transplant hearts.

KE I TH R . WAL L EY , MD , F RCPC , A B IM a St. Paul’s Hospital intensivist, is associate director of the iCAPTUR4E Centre / MRL

and assistant head of basic research in the St. Paul’sDepartment of Medicine. Dr. Walley’s research articulates themechanisms of decreased left ventricular contractility and ofother organ dysfunction during sepsis and examines the role of genotype on phenotype in sepsis and systemic inflammatorystates. He has shown how to measure left ventricular contractili-ty by using left ventricular pressure-volume relationships in

acute animal model experiments. Dr. Walley has also isolatedcardiac myocytes in tissue culture. He collaborates with Dr. James A. Russell and is one of the primary investigators in obtaining $17 million in infrastructure funding from theCanada Foundation for Innovation.

X IODONG WANG , PhD focusses his research on Ca2+ regulation in vascular endothelium. He uses both electrophysiological andCa2+ sensitive fluorescence imaging techniques to study ioniccurrents and Ca2+ regulation in freshly isolated endothelial cellsand in disease model for transplant vascular disease. This cellu-lar work is combined with complimentary studies on intactblood vessels in an organ bath system, RT-PCR and electronmicroscopy. Dr. Wang’s current projects include the studies ofCa2+ extrusion in native and diseased endothelium, effects ofoxidative stress and cytokines on Ca2+ extrusion and nuclearCa2+, and endothelium derived hyperpolarizing factor (EDHF).

PEARC E W I LCOX , MD , F RCPC is a clinician–researcher basedout of the iCAPTUR4E Centre / MRL. Dr. Wilcox, who completedhis research training at the University of British Columbia, is anAssociate Professor, in the UBC Faculty of Medicine and teachesextensively on respiratory medicine. Dr. Wilcox’s research inter-ests include adult cystic fibrosis, respiratory sleep disorders, respiratory medicine, ventilatory muscle disorders, pathophysi-ology and treatment, intermittent mechanical ventilation fortreatment of chronic hypercapnic respiratory failure, exercisephysiology, ventilatory muscle testing, and the effects of sepsisinflammatory mediators on ventilatory muscle.

DECHENG YANG , PhD is a molecular virologist who completed his PhD and postdoctoral research at the University of Illinoisand is primarily interested in the molecular biology and patho-genesis of viral myocarditis and the development of potentialantiviral treatments. Specifically, Dr. Yang is studying the mecha-nism of coxsackieviral translation initiation and the functionalanalysis of differentially expressed genes in hearts infected by coxsackie virus. He is an Honorary Professor of NankaiUniversity, People’s Republic of China.

Funding Over view

During the latter part of 2000, we had secured funding from several sources. The CFI committed $6,496,989 with a matchinggrant from the BCKDF (currently before the Treasury Board).The Blusson Foundation (UBC) committed $2,054,546 and theHeart and Stroke Foundation BC and Yukon, and the BC LungAssociation each contributed $400,000. A commitment of$1,193,949 was also pledged by vendors to match our invest-ments. To help make the iCAPTUR4E Centre /MRL a reality, St.Paul’s Hospital also committed over $1.5 million per year in ongo-ing operating support, primarily for support of personnel. A planis in the works to leverage these hard earned contributions into even more support for the ongoing operation of the Centre.

We want to thank all of our funders for their vision and beliefin the goals of The iCAPTUR4E Centre /MRL. This venture is a truepartnership in that we can only achieve our goals through aunique and cooperative funding structure.

Our Par tners

Canada Foundation for InnovationOn July 26, 2000, the Canada Foundation for Innovation awardedProject 2406 $6.5 million dollars towards the total project cost of $17 million. The government of Canada established the CFIin 1997. The Foundation’s goal is to strengthen the capability ofCanadian universities, colleges, research hospitals, and other not-for-profit institutions to carry out world-class research and tech-nology development. By investing in research infrastructure proj-ects, the CFI supports research excellence, and helps strengthenresearch training at institutions across Canada.

Brit ish Columbia Knowledge Development Fund (BCKDF)A matching 40 per cent of the project cost ($6.5 million dollars)was requested from the BCKDF. BCKDF is a $217 million program,providing capital funding to enhance research infrastructure forthe province’s public post-secondary institutions, teaching hospi-tals, and affiliated non-profit agencies. BCKDF is a matching pro-gram, providing up to 40 per cent of a project’s cost. In mostcases, the CFI (see above) provides 40 per cent of a project’scost, with other non-provincial-government sources providing the remaining 20 per cent. The iCAPTUR4E BCKDF application iscurrently before the provincial Treasury Board.

Providence Health Care, St. Paul ’s Hospital SiteProvidence Health Care has generously committed $1.5 milliondollars per year in ongoing operating support, and 20,000square feet of hospital space for the iCAPTUR4E Centre /MRL. St. Paul’s Hospital is a major teaching hospital of the University of British Columbia.

University of Brit ish ColumbiaThe University of British Columbia (UBC) is the official recipient of the CFI’s iCAPTUR4E infrastructure grant. UBC has recognizedresearch to be essential to the world-wide improvement of clinicalcare practices and has always been a long term supporter of the UBC McDonald Research Laboratories at St.Paul’s Hospital.The UBC Blusson Foundation funded 13 per cent of this awardor $2.1 million.

Heart and Stroke Foundation of BC and YukonThe Heart and Stroke Foundation has generously provided amatch of $400,000 towards non-CFI eligible expenses for theiCAPTUR4E Centre /MRL. This match will primarily be used forrenovation of educational space. The Heart and Stroke Foundationof BC and Yukon contributes $5 million annually to BC-basedresearch, all of which is raised through private donations andfundraising. They fund over 80 per cent of non-commercial heartand stroke research in BC, making them the largest fundingsource for such research in the province.

BC Lung Associat ionThe BC Lung Association has generously provided a match of$400,000 towards non-CFI eligible expenses for the iCAPTUR4ECentre /MRL. The BC Lung Association generally supports researchnnually in personnel and operating grants to the internationallyrecognized doctors, scientists and researchers studying lungdisease in British Columbia.

VendorsA projected $1.2 million dollars will be secured through in-kinddonations from iCAPTUR4E vendors. In-kind donations includespecial discounts on equipment, additional bonus products orfeatures, or training. IBM is the first major iCAPTUR4E vendor-partner. IBM will be providing most computer hardware and software to upgrade the computer infrastructure of iCAPTUR4E.

F U N D I N G , P A R T N E R S H I P S , A N D F U N D R A I S I N G

Funding for infrastructure is difficult to raise. That’s why theCanada Foundation for Innovation program is so important forCanadian researchers. However, the funds to maintain a highlytechnical and expertly staffed laboratory are not supplied by the CFI. To find operational support, we must continue efforts to raise funds in the private sector. The St. Paul’s HospitalFoundation and the UBC Development Office have been impor-tant partners for all researchers within St. Paul’s Hospital. Theyhave been successful at communicating the potential of ourresearch and how it relates to improvement of care.

We encourage corporate, private and individual donors tolook into our research and our capabilities with the help of theFoundation or the Development Office. Together, we can offerdonors a variety of ways to make concrete and recognized contri-butions to heart, lung and blood vessel research.

Options for donors include (but are not limited to):

• Naming of a specific laboratory or room at iCAPTUR4E;• Naming of a specific piece of equipment such as imaging

equipment;• Supporting specific research endeavours such as our precious

tissue bank;• Supporting the work of talented young researchers and

trainees through a named scholarship or bursary.

Because iCAPTUR4E represents such a unique passion of all partners, we want to build on this successful model by attractinglike-minded and results-oriented donors. We need donor champi-ons who can share in our vision for better health in order toallow iCAPTUR4E scientists to create a Canadian dynasty in heart,lung, and blood vessel research. Please join us!

E Y E I N G T H E F U T U R E : F U N D R A I S I N G

Refereed Publications:

Adler, L., Hill, J.S., and Frohlich, J. Chemicalprecipitation of apolipoprotein B-contain-ing lipoproteins facilitates determination ofLDL particle size. Clinical Biochemistry 33:187-190, 2000

Allard MF, Wambolt RB, Henning SL, Grist M,English DR, Rodrigues B, Bondy GP.Hypertrophied rat hearts are less respon-sive to the metabolic and functional effectsof insulin. Am J Physiol 279:E487-E493,2000

Alscher KT, Phang PT, McDonald TE, WalleyKR. Enteral feeding decreases gut apopto-sis, permeability, and lung inflammationduring murine endotoxemia. Am J Physiol.G569-76, 2001

Anderson GJ, Roswit WT, Holtzman MJ, HoggJC, van Eeden SF. Effect of mechanicaldeformation of neutrophils on theirCD18/ICAM-1 dependent adhesion. J ApplPhysiol 91:1084-90, 2001

Anis AH, Lynd LD, Wang XH, King G, SpinelliJJ, Fitzgerald M, Bai T, Paré P. Double trou-ble: impact of inappropriate use of asthmamedication on the use of health careresources. CMAJ 164(5): 625-31, 2001

Bai TR. Asthma exacerbations. Eur Resp Rev(in press)

Bai TR. Interaction of airway inflammationand neural mechanisms. Monaldi ArchChest Dis (in press)

Bernard GR, Ely EW, Wright TJ, Stasek JE,Russell JA, et al. Safety and dose-relation-ship of recombinant human activated pro-tein C (rh APC) on coagulopathy in severesepsis. Crit Care Med Nov. 2001

Bernard GR, Vincent JL, Laterre PF, LaRosa SP,Dhainaut JF, Lopez-Rodriguez A, SteingrubJS, Garber GE, Helterbrand JD, Ely EW,Fisher CJ Jr. Recombinant human protein CWorldwide Evaluation in Severe Sepsis(PROWESS) study group. Efficacy and safe-ty of recombinant human activated proteinC in severe sepsis. N Engl J Med 344:699-709, 2001

Bramley AM, Robinson PJ, Hegele RG, HayalkoAJ, Stephens NL, Schellenberg RR. Trachealsmooth muscle responses of guinea pigswith airway hyperresponsiveness inducedby antigen vs. respiratory syncytial virus.Exp Lung Res (in press)

Bramley AM, Thomson RJ, Perrin R,Schellenberg RR. Inhibition of antigen-induced airway hyperresponsiveness inguinea pigs with the elastase inhibitor SC-390261. Eur Respir J (in press)

Butany J, Allard MF. Pathology of ProstheticHeart Valves. In Canadian CardiovascularSociety Consensus Conference on the

Surgical Management of Valvular HeartDisease. Can J Cardiol (in press)

Cheung P, Yanagawa B, Zhang H, Wang A,Luo H, Esfandiarei M, Suarez A, Wilson JE,Carthy CM, McManus BM, Yang DC.Molecular mechanisms of cardiovirulenceand host cell responses in coxsackievirusB3 induced myocarditis. Recent Res DevVirol (in press)

Choy JC, Granville DJ, Hunt DWC, McManusBM. Endothelial cell apoptosis: biochemicalcharacteristics and potential implicationsfor atherosclerosis. J Mol Cell Cardiol33:1673-1690, 2001

Clee SM, Kastelein JJ, van Dam M, Marcil M,Roomp K, Zwarts KY, Collins JA,Roelants R,Tamasawa N, Stulc T, Suda T, Ceska R,Boucher B, Rondeau C, deSouich C,Brooks-Wilson A, Molhuizen HO, Frohlich J,Genest J Jr, Hayden MR. Age and residualcholesterol efflux affect HDL-cholesterollevels and coronary artery disease inABCA1 heterozygotes. J. Clin Invest2000;106 (10:1263-1270)

Cook RC, Goddard CM, Ashe KA, Chen K,Lichtenstein SV, Walley KR. Potential dele-terious effect of b-adrenergic stimulationduring warm-blood cardioplegia in rabbithearts. J Invest Surg 14:213-20, 2001

Cook RC, Parker S, Kingsbury K, Frohlich JJ,Abel JG, Gao M, Ignaszewski AP. Effectivetreatment of hyperhomocysteinemia inheart transplant patients with and withoutrenal failure. J Heart Lung Transplantation2001; 20(3):311-315

Cook VJ, Coxson HO, Mason AG, Bai TR.Bullae, bronchiectasis and emphysema in apatient with anorexia nervosa. Can Resp J8:361-5

Doabiasova M, Frohlich JJ. Effect of labelingof plasma lipoproteins with [3H]-choles-terol on values of esterification rate ofcholesterol in apo B lipoproteins depletedplasma (FERHDL). Journal of Lipid Research2000;41:1356-1357

Dobiasova M, Raslova K, Rauchova H,Vohnout B, Ptackova K, Frohlich J.Atherogenic lipoprotein profile in familieswith and without history of early myocar-dial infarction. Physiol. Res 2001;50:1-8

Dhingra VK, Uusaro A, Holmes CL, Walley KR.Attenuation of lung inflammation by adren-ergic agonists in murine acute lung injury.Anesthesiology Oct 2001

Dorscheid DR, Wojcik K, Yule K, Hamann KJ,White SR . Apoptosis of airway epithelialcells induced by corticosteroids. Am JRespir Crit Care Med (in press)

Dorscheid DR, Wojcik KR, Yule K, White SR.Role of cell-surface glycosylation in mediat-ing repair of human airway epithelial cell

monolayers. Am J Physiol Lung Cell MolecPhysiol 281:L982-92, 2001

Evans TW, Albert RK, Bion JF, Chiche J-D,Epstein SK, Fagon JY, Ranieri M, SznajderJI, Torres A, Walley KR. International con-sensus conferences in Intensive CareMedicine: Noninvasive pressure ventilationin acute respiratory failure. Am J Respir CritCare Med 163:283-291, 2001

Fernandes N, Brown G, Russell JA. Adrenalinsufficiency in the critically ill. Int Care Med27:1434, 2001

Fodor JG, Frohlich JJ, Genest JJG, McPherson RP,for the Working Group on Hypercho-lesterolemia and Other Dyslipidemias.Recommendations for the management andtreatment of dyslipidemia (Review). CMAJ2000;162(10):1441-1447

Francis M, Frohlich J. Coronary artery diseasein patients at low risk: Apolipoprotein AI as an independent risk factor. Athero-sclerosis 2001;155:165-170

Frangolias, DD, Wilcox PG. Predictability ofoxygen desaturation during sleep inpatients with cystic fibrosis from clinical,spirometric and exercise parameters. ChestFeb;119(2):434-41, 2001.

Frankl D, Tweeddale MG, Vedal S, Russell JA.Long term health outcomes in survivors ofthe acute respiratory distress syndrome.Crit Care Med (in press)

Fuji, T., Hayashi, S., Hogg, J.C. Vincent, R.,and van Eeden S.F. Particulate matter airpollutants induce cytokine expression inhuman bronchial epithelial cells. Am. J.Respir. Cell Mol. Biol. 25: 265-271 (2001)

Gilmour PS, Rahman I., Hayashi S, Hogg JC,Donaldson K, MacNee W. Adenoviral E1Aprimes alveolar epithelial cells to environ-mental particle-induced transcription ofinterleukin-8. Am J Physiol Lung Cell Mol.Physiol 281:598-606, 2001

Granville DJ, Cassidy BA, Ruehlmann D, ChoyJ, Ip S, Brenner C, Kroemer G, van BreemenC, Margaron P, Hunt DW, McManus BM,Mitochondrial release of apoptosis includ-ing factor (AIF) and cytochrome c duringsmooth muscle cell apoptosis. Am J Pathol159:305-311, 2001

Granville DJ, McManus BM, Hunt DWC.Photodynamic therapy: shedding light onthe biochemical pathways regulating por-phyrin-mediated cell death. HistolHistopathol 16:309-317, 2001

Granville DJ, Jiang H, McManus BM, HuntDWC. Photodynamic therapy in combina-tion with Fas ligand or TRAIL has an addi-tive effect upon the induction of apoptosisin Jurkat cells. Int Immunopharmacol1:1831-40, 2001

Granville DJ, Ruehlmann DO, Choy J, Cassidy

i C A P T U R 4 E C E N T R E / M R L

PublicationsS e p t e m b e r 2 0 0 0 t o S e p t e m b e r 2 0 0 1

BA, Thompson CB, Hunt DWC, vanBreemen C, McManus BM. Bcl-2 increasesemptying of endoplasmic reticulum Ca2+

stores during photodynamic therapy-induced apoptosis. Cell Calcium (in press)

Grover SA, Dorais M, Paradis, G, Fodor JG,Frohlich JJ, McPherson R, Coupal L, Zowall,H. Lipid screening to prevent coronaryartery disease: a quantitative evaluation ofevolving guidelines. CMAJ 2000; 163(10):1263-1269

Hamilton SJ, Allard MF, Friedman JM. Suddendeath and cardiac findings inNeurofibromatosis-1: A case report. Am JMed Genetics 100:95-9, 2001

Hegele RG, Ahmad HY, Becker AB, Dimich-Ward H, Ferguson AC, Manfreda J, WatsonWTA, Chan-Yeung M. The associationbetween respiratory viruses and symptomsin two week-old infants at high-risk forasthma and allergy. J Pediatrics 138: 831-7, 2001

Holmes C, Patel B, Russell JA, Walley KR.Physiology of vasopressin relevant to septic shock. Chest 120:989-1002, 2001

Holmes CL, Walley KR, Chittock DR, LehmanT, Russell JA. The effects of vasopressin onhemodynamics and renal function insevere septic shock: A case series. Int CareMed 27:1416-21, 2001

Hunninghake GW, Zimmerman MB, SchwartzD, King TE Jr, Lynch J, Hegele RG, Hogg J,Waldron J, Colby T, Muller N, Lynch D,Galvin J, Gross B, Toews G, Helmers R,Cooper JAD Jr, Baughman R, Strange C,Millard M, Stutzman J. Utility of lung biop-sy for the diagnosis of idiopathic pul-monary fibrosis. Am J Crit Care Med164:193-6, 2001

Joos L, McIntyre L, Ruan J, Connett JE,Anthonisen NR, Weir TD, Paré PD,Sandford AJ. Association of IL1 beta andIL1 receptor antagonist haplotypes withrate of decline in lung function in smokers.Thorax 56:863-6, 2001

Kanda T, Tanaka T, Sekiguchi K, Seta Y,Kurimoto M, Wilson JE, Nagai, Yang DC,McManus BM, Kobayashi I. Effect of interleukin-18 on viral myocarditis;enhancement of interforn-g and naturalkiller cell activity. J Mol Cell Cardiol 32:2163-2171, 2001

Kastelein JPJ, Isaacsohn JL, Ose L,Hunninghake DB, Frohlich J, Davidson MH,Habib R, Dujovne CA, Crouse JR, Liu M,Melino MR, O’Grady L, Mercuri M, MitchelY. Comparison of effects of simvastatin ver-sus atorvastatin on high-density lipopro-tein cholesterol and apolipoprotein A-I lev-els. American Journal of Cardiology 2000;86(2): 221-223.

King GG, Moore BJ, Seow CY, Paré PD. Airwaynarrowing associated with inhibition ofdeep inspiration during methacholineinhalation in asthmatics. Am J Respir CritCare Med 164(2): 216-218, 2001

Kuo KH, Wang L, Paré PD, Ford LE, Seow CY.

Myosin thick filament lability induced bymechanical strain in airway smooth mus-cle. J Appl Physiol. 90(5):1811-6, 2001

Lagaud G, Karicehti V, van Breemen C, ChristCJ, Laher I. Inhibitors of gap junction activ-ity attenuate myogenic tone in cerebralarteries. Am J Physiol (in press)

Laher I, Zhang JH. Protein kinase C and cere-bral vasospasm. J Cereb Blood Flow Metab.21(8):887-906, 2001

Lambert RK, Paré PD, Okazawa M. Stiffnessof peripheral airway folding membrane inrabbits. J Appl Physiol 90:2041-2047, 2001

Levin A, Duncan L, Djurdjev O, Shapiro RJ,Frohlich J, Belanger A, Dumas R, Ross S. Arandomized placebo-controlled double-blind trial of lipid lowering strategies inpatients with renal insufficiency: diet modi-fication with or without fenofibrate. ClinicalNephrology 2000;53(2):140-146

Lichtenstein AH, Jauhiainen M, McGladdery S,Ausman LM, Jalbert SM, Vilella-Bach M,Ehnholm C, Frohlich J, Schaefer EJ. Impactof hydrogenated fat on high densitylipoprotein subfractions and metabolism. JLipid Res 2001;42(4):597-604

Longnus SL, Wambolt RB, Barr RL, LopaschukGD, Allard MF. Regulation of myocardialfatty acid oxidation by substrate supply.Am J Physiol 281(4):H1561-7, 2001

Lynn EG, Frohlich J, Siow YL, O K.Lipoprotein-X stimulates monocyte chemo-taxis via a mechanism involving MCP-1expression in mesangial cells. Accepted toKidney Int 2001

Lui AH, McManus BM, Laher I. Endothelialand myogenic regulation of coronary arterytone. Eur J Pharmacol 410:25-31, 2000

Maass-Moreno RT, Burdyga RW, Mitchell C,Seow CY, Ragozzino J, Ford LE. Simplefreezing apparatus for resolving rapidmetabolic events associated with smoothmuscle activation. J Appl Physiol 90:2453-2459, 2001

MacIntyre L, Walley KR. Importance of under-lying mechanism and genotype on out-come of sepsis trials. Crit Care Med.29:677-679, 2001

Mahenthiralingam E, Frangolias D, VandammeP, Campbell M, Henry D, Gravelle A, WongL, Davidson G, Wilcox P, Nakielna B, SpeertD. Infection of cystic fibrosis patients withbacteria of the Burkholderia CepaciaComplex: Epidemiology and clinical out-come. Clin Infect Dis Nov 1; 33(9)1469-1475, 2001.

Martel H, Walker DC, Reed RK, Bert JL.Dermal fibroblast morphology is affectedby stretching and not by C48/80.Connective Tissue Res. 42:1-10. 2001.

McDonald PC, Wilson JE, McNeill S, Gao M,Spinelli J, Rosenberg F, Wiebe H, McManusBM. The challenge of defining normality forhuman mitral and aortic valves: geometri-cal and compositional analysis. CardiovascPathol (in press)

McDonald PC, McManus BM. Fen-Phen valve

disease: A real entity?. Pathology CaseReviews (in press)

McDonald TE, Grinman MN, Carthy CM, WalleyKR. Endotoxin infusion in rats inducesapoptotic and survival pathways in theheart. Am J Physiol 279:H2053-H2061,2000

McGladdery SH, Pimstone SN, Clee SM,Bowden JF, Hayden MR, Frohlich J.Common mutations in the lipoproteinlipase gene (LPL): Effects on HDL-choles-terol levels in a Chinese Canadian popula-tion. Atherosclerosis 2001;156:401-407

McGladdery SH, Frohlich JJ. Lipoprotein lipaseand apolipoprotein E polymorphisms:Relationship to hypertriglyceridemia associ-ated with pregnancy. Journal of LipidResearch 2001 (in press)

McGuinness, C, Seccombe DW, Frohlich JJ,Ehnholm C, Sundvall, J, Steiner, G for theDAIS Project Group. Laboratory standardi-zation of a large international clinical trial– the DAIS experience. ClinicalBiochemistry 2000; 33 (1):15-24

Meshi B, Vitalis T, Ionescu D, Hayashi S, HoggJC. Emphysematous lung destruction bycigarette smoke: effect of latent adenovirus5 infection and retinoic acid treatment. AmJ Respir Cell Mol Biol 25:1-6, 2001

Miller LM, Granville DJ, Narula J, McManusBM. Apoptosis in cardiac transplant rejec-tion. Cardiol Clinic 19:141-154, 2001

Mitchell RW, Seow CY, Burdyga T, Maass-Moreno R, Pratusevich VR, Ragozzino J,Ford LE. Relationship between myosinphosphorylation and contractile capabilityof canine airway smooth muscle. J ApplPhysiol 90:2460-2465, 2001

Moghadasian M, Frohlich J, McManus BM.Advances in experimental dyslipidemia and atherosclerosis. Lab Invest 81:1173-83,2001

Moghadasian M., McManus, B.M., NguyenL.B., Shefer S., Nadji M., Godin D.V., GreenT.J., Hill J., Yang Y., Scudamore C.H.,Frohlich J.J. Pathophysiology of apolipopro-tein E deficiency in mice: Relevance to apoE-related disorders in humans. FASEBJournal 15: 2623-2630, 2001.

Moghadasian MH, Mancini GBJ, Frohlich JJ.Pharmacotherapy of hypercholesterolemia:statins in clinical practice. Exp. Opin.Pharmacother 2000;(4):683-695

Moghadasian MH, Frohlich JJ. Statins andbones. CMAJ 2001;164(1):803-805

Moghadasian MH, Frohlich JJ, Saleem M, Jong-Myeon H, Qayumi, K, Scudamore CH.Surgical management of dyslipidemia:Clinical and experimental evidence. JInvestigative Surgery 2001;14:71-78.

Moghadasian MH, Nguyen LB, Shefer S, SalenG, Batta AK, Frohlich JJ. Hepatic cholesteroland bile acid synthesis, LDL receptor func-tion, and plasma and fecal sterol concen-trations: Comparison between wild-typeand apo E-deficient mice and the effects oftwo cholesterol-lowering agents.

Metabolism 2001;50:708-714.Moghadasian MH, Salen G, Frohlich JJ,

Scudamore CH. cerebrotendinous xan-thomatosis: A rare disease with diversemanifestations. Arch Neurol 2001 (in press).

Moghadasian MH, Nguyen LB, Shefer S, Nadji M, Green TJ, Ying Y, Hill J, ScudamoreC, Frohlich JJ. Pathophysiology of apo Edeficiency in mice: Relevance to apo E-related abnormalities in humans. FASEB J2001 (in press)

Mukae H , Vincent R, Quinlan K, English D,Hards J, Hogg JC, van Eeden SF. The effectof repeated exposure to Particulate AirPollution (PM10) on the Bone Marrow. Am JResp Crit Care Med 163:1-9, 2001

Mukae H, Hogg JC, English D, Vincent R, vanEeden SF. Phagocytosis of particulate mat-ter air pollutants (PM10) by HumanAlveolar Macrophages Stimulates the BoneMarrow. Am J Physiol (Lung Mol Biol)279:L924-L931: 2000

Murray K.R., Nair M.P., Ayyobi A.F., Hill J.S.,Pritchard P.H., Lacko A.G. Probing the 121-136 domain of lecithin:cholesterol acyltransferase using antibodies. Archivesof Biochemistry and Biophysics 385: 267-275, 2001

Patel BM, Chittock DR, Russell JA, Walley KR.Beneficial effects of short term vasopressininfusion during severe septic shock.Anesthesiology (in press)

Press N, Bai TR, Montessori V, Montaner J.Respiratory failure due to proteaseinhibitor related lipodystrophy in a patientwith compromised lung function. Can RespJ 8: 279-283, 2001

Rahimian R, Masih-Khan E, Lo M, vanBreemen C, McManus BM, Dube GP:Hepatic over-expression of peroxisome proliferator activated receptor g2 in the ob/ob mouse model of non-insulindependent diabetes mellitus. Mol CellBiochem 224:29-37, 2001

Raslova K, Smolkova B, Vohnour B,Gasparovic, J, Frohlich JJ. Risk factors foratherosclerosis in survivors of myocardialinfarction and their spouses: comparisonto controls without personal and familyhistory of atherosclerosis. Metabolism2001;50(1):24-29

Retamales I, Elliott WM, Meshi B, Coxson HO,Paré PD, Sciurba FC, Rogers RM, HayashiS, Hogg JC. Amplification of Inflammationin Emphysema and Its Association withLatent Adenoviral Infection. Am J RespirCrit Care Med 164:469-473, 2001

Russell JA, Singer J, Bernard GR, DrummondAJ, Walley KR, and The Ibuprofen in SepsisStudy Group. Changing pattern of organdysfunction in early human sepsis is relat-ed to mortality. Critical Care Medicine 28:3405 – 3411, 2000

Sandford AJ, Chagani T, Weir TD, Connett JE,Anthonisen NR, Paré PD. Susceptibilitygenes for rapid decline of lung function in

the lung health study. Am J Respir Crit CareMed 163:469-473, 2001

Sandford AJ, Zhu S, Bai TR, Fitzgerald JM,Paré PD. The role of the C-C chemokinereceptor-5 Delta 32 polymorphism in asthma and in the production of regulatedon activation, normal T cells expressedand secreted. J Allergy Clin Immunol108:69-73, 2001

Sato Y, Hogg JC, English D, van Eeden SF.Endothelin-1 changes polymorphonuclearleukocytes deformability and CD11b expres-sion and promotes their retention in thelung. Am J Resp Cell Mol Biol 23:404-410,2000

Sato K, Dohi Y, Miagawa K, Takase H, KojimaM, van Breemen C. The role of calciumsensitive protein kinase C in phenylephrineenhancement of calcium sensitivity in therat trail artery. J Cardiovasc Pharmacol (inpress)

Seow CY. Response of arterial smooth muscleto length perturbation. J Appl Physiol 89:2065-2072, 2000

Seow CY, Fredberg JJ. Historical perspectiveon airway smooth muscle: the saga of a frustrated cell. J Appl Physiol 91(2):938-52, 2001

Seow CY, Pratusevich VR, Ford LE. Series-to-parallel transition in the filament lattice ofairway smooth muscle. J Appl Physiol89(3):869-76, 2000

Seow CY, Wang L, Paré PD. Airway narrowingand internal structural constraints. J ApplPhysiol 88:527-533, 2000

Seow CY, Paré PD. Can airways close com-pletely? J Appl Physiol 89:2521-2522, 2000

Seow CY, White HD, Ford LE. Effects of substi-tuting uridine triphosphate for ATP on thecrossbridge cycle of rabbit muscle. JPhysiol (in press)

Signore PE, Machan LS, Jackson JK, Burt H,Bromley P, Wilson JE, McManus BM:Complete inhibition of intimal hyperplasiaby perivascular paclitaxel in balloon-injuredrat carotid arteries. J Vasc Interv Radiol12:79-88, 2001

Sniderman AD, Bergeron J, Frohlich J. ApoBand ApoAI versus lipoprotein lipids: Vitallessons from the TexCAPS/AFCAPS trial.CMAJ 2001;164(1):44-47

Suwa T, Hogg JC, English D, van Eeden SF.Interleukin-6 induces demargination ofintravascular neutrophils and shortenstheir transit in marrow. Am J Physiol (HeartCirc Physiol) 279:H2954-H2960, 2000

Suwa T, Hogg JC, Klut ME, Hards J, van EedenSF. Interleukin-6 changes deformability ofNeutrophils and induces their sequestra-tion in the lung. Am J Respir Crit Care Med163:970-976, 2001

Suwa T, Hogg JC, Vincent R, Mukae H, Fujji T,van Eeden SF. Ambient air particles stimu-lates alveolar macrophages of smokers topromote differentiation of myeloid cells.Exp Lung Res (in press)

Tanaka T, Kanda T, McManus BM, Kanai H,

Akiyama H, Sekiguchi K, Yokoyama T,Kurabayashi M. Overexpression of inter-leukin-6 aggravates viral myocarditis:impaired increase in tumor necrosis factor-alpha. J Mol Cell Cardiol 33:1627-35, 2001

Taylor L, Carthy C, Yang DC, Saad K, Wong D,Schreiner G, Stanton LW, McManus BM.Host gene regulation during coxsackievirusB3 infection in mice: Assessment bymicroarrays. Circ Res 87:328-335, 2000

Terashima T, Amakawa K, Matsumaru A, vanEeden SF, Hogg JC, Yamaguchi K. BALinduces an increase in peripheral bloodneutrophils and cytokine levels in healthyvolunteers and patients with pneumonia.Chest 119;1724-1729, 2001

Tsang S, Hayashi M, Zheng X, Campbell A,Schellenberg RR. Simplified purification ofhuman basophils. J Immunol Methods233:13-20, 2000

Uusaro A, Chittock DR, Russell JA, Walley KR.Stress test and gastric-arterial Pco2measurement improve prediction of successful extubation. Crit Care Med 28:2313-2319, 2000

Uusaro A, Takala J, Russell JA, Walley KR.Gastric mucosal-arterial CO2 gradient does not reflect systemic or splanchnicoxygenation after cardiac surgery Shock4:167-173, 2000

van Eeden SF, Hogg JC. The response ofhuman bone marrow to chronic cigarettesmoking. Eur Respir J 15:915-921, 2000

van Eeden SF, Tan WC, Suwa T, Mukae H,Terashima T, Fujii T, Qui D, Vincent R, HoggJC. Cytokines involved in the systemicinflammatory response induced by expo-sure to particulate matter air pollutants(PM10). Am J Respir Crit Care Med 164:826-30, 2001

Volpatti C, Leathley M, Walley KR, Dodek PM.Time-weighted nursing demand is a betterpredictor than midnight census of nursingsupply in an Intensive Care Unit. J Crit Care15:147-150, 2000

Wambolt RB, English DR, Lopaschuk GD,Brownsey RW, Allard MF. Dichloroacetateimproves post-ischemic function of hyper-trophied rat hearts. J Am Coll Cardiol36:1378-1385, 2000

Wambolt RB, Grist M, Bondy GP, Allard MF.Accelerated glycolysis and greater post-ischemic dysfunction in hypertrophied rathearts are independent of coronary flow.Can J Cardiol 17(8):889-94, 2001

Wang A, Cheung PKM, Carthy CM, Zhang H,Bohunek L, Wilson JE, McManus BM, YangDC. Specific inhibition of coxsackievirus B3 translation and replication by phospho-rothioate antisense oligodeoxynucleotides.Antimicrob Agents Chemother 45:1043-1052, 2001

Wang L, Paré PD, Seow CY. Selected contribu-tion: Effect of chronic passive lengthchange on airway smooth muscle length-tension relationship. J Appl Physiol 90:734-740, 2001

Wang L, Paré PD, Seow CY. Effect of chronicpassive length change on airway smoothmuscle length-tension relationship J ApplPhysiol 90:734-740, 2001

Wang X, Kim SU, van Breemen C, McLarnonJG. Activation of purinergic P2x receptorsinhibits P2y mediated Ca2+influx in humanmicroglia. Cell Calcium 27(4):205-212, 2000

White SR, Wojek K, Gruenert D, Sun S,Dorscheid DR. Airway epithelial cell woundrepair mediated by alpha-dystroglycan. AmJ Respir Cell Mol Biol 24:179-186, 2001

White SR, Kies P, Wojek K, Sun S, HiemstraPS, Rabe KF, Dorscheid DR. The role foractin cytoskeleton rearrangements in air-way epithelial cell apoptosis. Am J RespirCell Mol Biol 24:282-294, 2001

Xiang X, Qui D, Hegele RG, Tam WC.Comparison of different methods of totalRNA extraction for viral detection in spu-tum. J Virol Methods (in press)

Xiang X, Qui D, Hegele RG, Tan WC.Comparison of different methods of totalRNA extraction for viral detection in spu-tum. J Virol Methods 94:129-135, 2001.

Yamada K, Elliott WM, Hayashi S, BrattsandR, Roberts C, Vitalis T, Hogg JC. Latent adenoviral infection modifies the steroidresponse in allergic lung inflammation. J Allergy Clin Immunol 106:844-51, 2000

Yang DC, Hwang D, Quiu Z, Gillam S.Mutational analysis of rubella virus E1 glycoprotein for membrane fusion activity. J Virol (in press)

Non-Refereed Publications:

Allard MF, Stanley WC, Lopaschuk GD.Metabolic effects of glucose-insulin-potassi-um (GIK) on the heart. Heart Metabol 7:2-9, 2000

Baigorri F, Artigas A, Russell JA. Nivales supra-normales de transporte de oxigeno en eltratamiento enfermo critico: Un objectiveapropiado de la resucitacion. MedIntensiva (in press)

He JQ, Joos L, Sandford AJ. Recent develop-ments in the genetics of asthma - pharma-cogenomics considerations.Pharmacogenomics (in press)

Joos L, Paré PD, Sandford AJ. b2-Adrenergicreceptor polymorphisms and asthma. CurrOpin Pulm Med 7:69-74, 2001

Joos L, Sandford AJ. Genotype predictors ofresponse to asthma medications. Curr OpinPulm Med (in press)

Joos L, Paré PD, Sandford AJ. Genetic risk fac-tors for chronic obstructive pulmonary dis-ease. Swiss Med Wkly (in press)

Sambandam N, Brownsey RW, Allard MF.Energy metabolism of the hypertrophiedheart. Heart Failure Rev (in press)

Sandford AJ, Paré PD. Genetic risk factors forchronic obstructive pulmonary disease. ClinChest Med 21: 633-643, 2000

Pare, P. Youthful inspiration. Can Respir J8:231, 2001.

Book Chapters:

Bai TR. Mechanisms of action of beta adrenergic agonists and short acting b2therapy. In: Evidence Based AsthmaManagement. eds, Fitzgerald MF, Ernest P,Boulet LP, O’Byrne P. B.C. Decker Inc.,Hamilton, Ontario, 2001, Chapter 12; pp. 137-149

Bai TR, Knight DA. Role of the nervous sys-tem in airway remodelling. In: AirwayRemodelling. eds, Howarth P, Pauwels R.Lung Biology in Health and Disease, MarcelDekker Inc. New York, 2000, Vol 109; pp.147-165

Bosan S, Walley KR. Models of tissue oxygenuptake and microcirculatory blood flow. In:Respiratory-Circulatory Interaction in Healthand Disease. eds, Scharf S, Pinsky M,Magder S. Marcel Dekker Inc., New York,NY, 2001, (in press)

Burns AR, Walker DC, Smith CW. RelationshipBetween Tight Junctions and LeukocyteTransmigration. In: Tight Junctions Ed.Cereijido M, Anderson J. CRC Press, BocaRaton U.S.A., Pp. 629-652, 2001.

Cheung PM, Yanagawa B, Zhang H, Wang A,Luo H, Esfandiarei M, Suarez A, Wilson JE,Carthy C, McManus BM, Yang DC. Molecularmechanisms of cardiovirulence and hostcell responses in coxsackievirus B3induced myocarditis. Transworld ResearchNetwork, India (in press)

Dorscheid DR, Hall JB, Schmidt GA. CriticalIllness. In: Medical Disorders DuringPregnancy, eds, Barron, WM andLindheimer, MD, Mosby, St Louis, MO,2000, Chapter 7; pp. 229-266

Forrest DM, Russell JA, Montaner JSG. AIDS in the Intensive Care Unit: Focus on pneumocystis carinii pneumonia. In:Current Opinion in Critical Care. Volume 5;Issue 5, (in press)

Hegele RG, Hogg JC. Mechanisms of virus-induced asthma. In: Asthma andRespiratory Infections. ed, Skoner DP.Marcel Dekker Inc., New York, 2001, pp. 89-102

Holmes C, Russell JA, Walley KR. Sepsis: Isthere room for vasopressin? In, Sepsis,2001, 4(2):169 - 175

Joos L, Sandford AJ, Paré PD. Genetic risk factors. In: Chronic Obstructive LungDisease. eds, Voelkel NF, MacNee W. B.C.Decker Inc., Hamilton, Ontario, 2001, (in press)

Holmes CL, Walley KR. Cardiovascular management of ARDS. In: AcuteRespiratory Distress Syndrome. Seminars inRespiratory and Critical Care Medicine. eds,Thieme, Hall JB, Schmidt G. New York, NY,2001 (in press)

McManus BM, Kandolf R. Myocarditis. In:Atlas of Cardiovascular Pathology, ed,McManus BM. Current Medicine,Philadelphia, 2000, pp. 168-183

McManus BM, Winters G. Myocarditis. In:Silver’s Textbook of CardiovascularPathology. Churchill Livingston, New York,2001, pp. 250 – 284

McManus BM, Harji S, Wood S. Morphologicalfeatures of normal and abnormal conduc-tion system: essentials for interventionalelectrophysiologists. In: InterventionalElectrophysiology. ed, Singer I, ed. 2nd ,Lippincott Williams and Wilkins, Baltimore,MD, 2001, pp. 3-55.

Sandford AJ, Weir TD, Paré PD. Genetics ofasthma. In: Evidence-based asthma man-agement. eds, FitzGerald JM, Ernst P,Boulet L-P, O’Byrne PM, B.C. Decker Inc.,Hamilton, Ontario. 2000, pp.13-26

Sandford AJ, Weir TD, Paré PD. Genetics ofCOPD and emphysema: diagnosis applica-tions and therapeutic perspectives. In:Clinical Management of COPD. eds,Similowski T, Whitelaw WA, Derenne J-P.Marcel Dekker Inc., New York, 2001, pp. 221-243

Walley KR. Gas exchange in the heart. In:Pulmonary and Peripheral Gas Exchange inHealth and Disease. eds, Roca J,Rodriguez-Roisin R, Wagner PD. MarcelDekker Inc., New York, NY, 2000, pp 359-381

Yanagawa B, Cheung PM, Esfandiarei M,Carthy CM, Yang DC, McManus BM. Lifeand death signaling in CVB3 inducedmyocarditis In: Myocarditis: FromBenchside to Bedside. ed, Cooper L. (in press)

Yang DC, Taylor L, Carthy CM, Wang A, Luo Z,Cheung PMK, Bohunek L, Schreiner G,McManus BM. Cardiovascular genomics -applications to myocarditis. In: Methods inMolecular Medicine. Humana Press, USA(in press)

Books:

1. McManus BM (ed): Atlas of CardiovascularPathology for the Clinician. Braunwald E(series ed), Current Medicine, Philadelphia,2000, pp 1-290.

2. Radiologic Diagnosis of Diseases of theChest. Muller NL, Fraser RS, Colman NCand Pare PD. WB Saunders, Philadelphia,2001

i C A P T U R 4 E C E N T R E / M R L

Earned GrantsS e p t e m b e r 2 0 0 0 t o S e p t e m b e r 2 0 0 1

R E S E A R C H E R A W A R D T I T L E A G E N C Y

Allard, Michael $ 45,000.00 Operating Grant Vancouver Foundation

Allard, Michael 11,638.00 Glycogen Turnover and Glycolytic Capacity in the Hypertrophied Heart Heart & Stroke Foundation

Allard, Michael 93,314.00 Regulation of Carbohydrate Oxidation in Cardiac Hypertrophy Heart & Stroke Foundation

Allard, Michael 77,889.00 Glycogen Turnover and Glycolytic Capacity in the Hypertrophied Heart CIHR

Allard, Michael 84,000.00 Cardioprotective Effects of Trimetazidine in Pressure-Overload Hypertrophied Hearts Institut de RecherchesInternationales Servier

Allard, Michael 29,935.00 UV/visible Spectrophotometer Equipment Grant Heart & Stroke Foundation

$ 341,776.00

Bai, Tony 40,651.00 Modulation of Airway Function by Neurotrophic Cytokines CIHR

Bai, Tony 46,196.00 Neuroregulation and Modulation of Inflammation in the Lung by Leukemia CIHRInhibitory Factor

Bai, Tony 21,992.00 A Randomized, Double Blind, Placebo-Controlled Phase II Study of the Safety Intermune and Efficacy of Subcutaneous Recombinant Interferon-y1b in patients With Pharmaceuticals Inc.Idiopathic Pulmonary Fibrosis

$108,839.00

Dorscheid, Delbert 7,000.00 Faculty Start-Up Medicine Research Coordinating Committee

Dorscheid, Delbert 50,000.00 Dexamethasone-Induced Airway Epithelial Cell Apoptosis VPR Discretionary Research Fund

Dorscheid, Delbert 28,000.00 Mechanisms of Airway Epithelium Apoptosis NIH

Dorscheid, Delbert 57,000.00 Corticosteroid-Induced Airway Epithelial Cell Apoptosis Parker B. Francis Fellowship

$142,000.00

Frohlich, Jiri 76,023.00 Effective Exercise Modality to Reduce Insulin Resistance in Type 2 Diabetic Women Heart & Stroke Foundation

Frohlich, Jiri 21,678.00 Atherosclerosis Progression and Low HDL Ruesch International Inc.

Frohlich, Jiri 15,520.00 Diabetes Atherosclerosis Intervention Study Laboratories Fournier S.C.A.

Frohlich, Jiri 159,630.00 Cholesterol and Anti-Athersclerotic Effects of Phyosterols: Possible Synergistic Forbes Medi-Tech Inc. Effects of Omega-3 Fatty Acids and Tocotrienols

Frohlich, Jiri 78,656.00 Influence of Phytosterols and Phytostanols Added to Butterfat on Plasma Forbes Medi-Tech Inc. Cholesterol Levels in Hypercholesterolemic Humans

Frohlich, Jiri 66,701.00 A 24-Week Randomized Double-Blind Multicenter Trial to Evaluate the Efficacy Zeneca Pharma Inc.and Safety of Starting and Maximum Doses of ZD4522and Atorvastatin in the Treatment of Subjects With Hypercholesterolemia and Documented Atherosclerosis

Frohlich, Jiri 18,259.00 Relationship Between Skin Cholesterol, Carotid Ultrasound, Endothelial IMI InternationalDysfunction and Systemic Markers of Atherosclerosis Risk

Frohlich, Jiri 8,872.00 A Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Merck Frosst Canada & Co. Lipid-Altering Efficacy, Safety and Tolerability of SCH 58235 When Added to Ongoing Therapy with an HMG-CoA Reductase Inhibitor (Statin)

Frohlich, Jiri 13,344.00 Modulation of Arterial Reactivity Using Amlodipine and Atorvastatin Measured Pfizer by Ultrasound Examination

Frohlich, Jiri 11,576.00 Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Study of SD-5613 Searle Canada Ltd.as Monotherapy and in Combination Therapy with Atorvastatin (Assessment of Cholesterol Reduction by an Inhibitor of the Ileal Bile Acid Transporter)

Frohlich, Jiri 12,848.00 A Multicentre, Double Blind, Randomized, Parallel 36 Week Dose Escalation Study Merck Frosst Canada Inc. to Evaluate the Efficacy and Safety of Simvastatin 40 and 80mg/day Versus Atorvastatin 20, 40 and 80md/day in patients With Hypercholesterolemia

Frohlich, Jiri 6,200.00 The Heart Outcomes Prevention Evaluation -The Ongoing Outcome Study McMaster University

Frohlich, Jiri 28,350.00 A Multinational, Multicenter, Randomised, Double-Blind, Parallel Group, Dose NegmaRanging Study to Evaluate the Efficacy and Safety of NK-104 1mg, 2mg, 4mg and 8mg compared to Placebo in Patients with Primary or Combine Hyperlipidemia

$517,657.00

Hayashi, Shizu 22,600.00 Regulation of Inflammatory Mediator Expression by Adenovirus E1A in COPD BC Lung AssociationHogg, James

Hayashi, Shizu 20,517.00 Regulation of Transcription Factor Activation by Adenovirus E1A in COPD BC Lung Association

$43,117.00

Hegele, Richard 92,825.00 Lung Viruses CIHR

Hegele, Richard 28,671.00 Viral Factors in the Onset of Childhood Asthma BC Lung Association

$121,496.00

Hill, John 63,400.00 Structure-Function Relationships of Hepatic Lipase and Lip0protein Lipase Heart & Stroke Foundation

$63,400.00

Hogg, James 113,430.00 Structure and Function of the Bronchial Mucosa CIHRHayashi, Shizu

Hogg, James 123,009.00 Structure and Function of Pulmonary Vasculature CIHRVanEeden, Stephan

Hogg, James 51,716.00 Leukocyte Kinetics and the New Cigarette R.J. Reynolds Tobacco Co.

Hogg, James 174,137.00 Evaluation for a New Treatment for Emphysema Glaxo Wellcome Inc.

Hogg, James 315,000.00 Role of Latent Adenoviral Infection in the Pathogenesis of Emphysema NIHHayashi, ShizuSandford, AndrewWalker, DavidVanEeden, Stephan

Hogg, James 81,038.00 The Determinants of Steroid Resistance in COPD Glaxo Wellcome Inc.

Hogg, James 10,130.00 The Determinants of Steroid Resistance in COPD MRC/PMACParé, PeterHayashi, Shizu

Hogg, James 564,055.55 Pathologic Assessment of Lung Volume Reduction Surgery NIH

Hogg, James 93,800.00 Atmospheric Pollution and Cardiovascular Disease Health CanadaVanEeden, Stephan

Hogg, James 210,726.16 Compound Screening in a Guinea Pig Smoking Model Glaxo Wellcome Inc.

Hogg, James 203,714.00 Effects of Bayer Compounds and Reference Compounds on Lung Inflammation Bayer AG in Guinea Pigs

Hogg, James 400,000.00 McDonald Research Laboratories Research Support SPH Foundation

Hogg, James 227,572.00 Provincial Pulmonary Referral Clinic St. Paul’s Hospital

$2,568,327.71

Karsan, Aly 75,397.00 Mechanisms of Tumor Angiogenesis: The Role of Notch 4/Jagged Interactions National Cancer Institutes

Karsan, Aly 28,185.00 Major Equipment Grant Heart & Stroke Foundation

Karsan, Aly 207,051.00 Generation of Autologous Endothelial Cells for Tumor-Directed Therapy National Cancer Agencies

Karsan, Aly 73,042.00 Mechanisms of Angiogenesis in Ischemic Vascular Disease Heart & Stroke Foundation

Karsan, Aly 30,000.00 Structure-Function Studies of the Bc1-2 Family Members, A1, in Human Endothelial CIHR

Karsan, Aly 96,900.00 Endothelial Cell Apoptosis: Lipopolysaccaride Signals CIHR

Karsan, Aly 85,875.00 Molecular Mechanisms of Endothelial Survival/Apoptosis Heart & Stroke Foundation

$596,450.00

McManus, Bruce 167,464.00 Cardiovascular Research St. Paul’s Hospital

McManus, Bruce 500,000.00 VVBRC: Biophysical and Pathobiological Evaluation of Human Blood Vessels SPH Foundation500,000.00 VVBRC: Biophysical and Pathobiological Evaluation of Human Blood Vessels Eli Lilly Canada Inc.

McManus, Bruce 24,650.00 VEGF in Endothelial Permeability & Cell Viability in Transplant Vascular Disease Heart & Stroke Foundation123,499.00 VEGF in Endothelial Permeability & Cell Viability in Transplant Vascular Disease CIHR

McManus, Bruce 63,025.00 Endothelial and Smooth Muscle Injury in the Pathogenesis of Transplant Heart & Stroke FoundationVanBreemen, Casey Vascular Disease

McManus, Bruce 70,992.00 Myocyte Death in Myocarditis: Coxsackievirus Modification of Host Cell CIHRYang, Decheng Death Machinery

McManus, Bruce 50,000.00 Toward Quelling the Heart Failure Epidemic CIHR Opportunity ProgramWalley, Keith

McManus, Bruce 86,500.00 Survival Signalling in Coxsackievirus-Induced Myocarditis Heart & Stroke Foundation

McManus, Bruce 44,122.00 VEGF in Endothelial Permeability & Cell Viability in Transplant Vascular Disease - Heart & Stroke FoundationEquipment Grant

McManus, Bruce 175,000.00 Signalling in Initiation and Acceleration of Lipid-Rich Transplant Vascular Disease Heart & Stroke Foundation

McManus, Bruce 100,000.00 Cardiovascular Research University of British Columbia

McManus, Bruce 75,000.00 Inflammatory Cardiovascular Diseases CIHR

McManus, Bruce 34,300.00 Cellular Mechanisms of Estogen Enhancement of Endothelial Nitric Oxide (NO) MRC/PMACProduction - Fellowship - Roshaniak Rahimian

$2,014,552.00

Paré, Peter 63,969.00 Leukocyte Kinetics in the Bronchial Circulation CIHR

Paré, Peter 22,000.00 The Effects of Airway Wall Thickness, Airway Stretch and Steroid Therapy on BC Lung Association Airway Mechanisms in Asthma Assessed Using High Resolution CT scanning

Paré, Peter 67,766.00 Human Airway Smooth Muscle Function and Bronchial Hyperresponsiveness CIHRSchellenberg, RobertWalker, David

Paré, Peter 64,097.00 Susceptibility Genes for COPD CIHRSandford, Andrew

Paré, Peter 301,980.00 Remodeling of Human Airways in Disease NIHHogg, JamesHayashi, ShizuCoxson, HarveyElliott, Mark

Paré, Peter 293,061.00 A Two-Year, Multi-Site Family Study to Identify the Genetic Determinants Glaxo Wellcome IncSandford, Andrew Associated with Susceptibility to Chronic Obstructive Pulmonary Disease

$812,873.00

Russell, James 250,000.00 Tissue Pathway Factor Inhibitor in Sepsis Chiron

Russell, James 347,059.00 Clinical Centers for the Clinical Network for the Treatment of Adult National Institutes Respiratory Distress Syndrome (ARDSnet) of Health (US)

Russell, James 40,000.00 Low Volume Ventilation Trial Canadian InstitutesMeade, M. of Health ResearchStewart, T.

$637,059.00

Sandford, Andrew 22,043.00 The Role of Adenovirus in COPD: Integration of Viral DNA and Genetic BC Lung AssociationHayashi, Shizu Susceptibility of the Host

Sandford, Andrew 68,445.00 Candidate Genes for Asthma and Atopy in a Cohort of at Risk Infants CIHRParé, Peter

Sandford, Andrew 7,000.00 New Faculty Start-Up Medical ResearchCoordinating Committee

Sandford, Andrew 50,000.00 Investigation of the Genetic Basis of Chronic Obstructive Pulmonary Disease VPR Discretionary Research Fund

Sandford, Andrew 80,183.00 Genotype-Phenotype Association in Human Inflammatory Airway Disease UBC Blusson Fund (20%)

Dorscheid, Del 160,386.00 Genotype-Phenotype Association in Human Inflammatory Airway Disease CFI: New Opportunities (40%)

160,386.00 Genotype-Phenotype Association in Human Inflammatory Airway Disease BCKDF: Knowledge Development Grant (40%)

Sandford, Andrew 58,800.00 Candidate Genes for Asthma and Atopy in a Cohort of at Risk Infants Parker B. Francis Fellowship

$607,243.00

Schellenberg, Robert 56,202.00 Mechanisms of Aspirin-Induced Asthma and Polyposis CIHR

Schellenberg, Robert 20,600.00 Role of Basophils in Allergic Inflammation BC Lung Association

$76,802.00

Tsang, John 21,300.00 The Roles of Endothelins and Their Antagonists in Pulmonary Embolism BC Lung Association

$21,300.00

Van Breemen, Cornelius 55,197.00 Calcium Gradients in Vascular Smooth Muscle Heart & Stroke Foundation

Van Breemen, Cornelius 60,572.00 Receptor Mediated C2+ Entry in Native Endothelium CIHR

Van Breemen, Cornelius 85,408.00 Experimental Design: Does BMS Decrease (Ca2+)i or Inhibit Ca2+ Sensitivity? BMS Pharmaceutical

Van Breemen, Cornelius 15,462.00 Calcium Gradients Regulate Endothelial Secretions - Fellowship - Guy Lagaud Heart & Stroke Foundation

$216,639.00

VanEeden, Stephan 21,000.00 Bone Marrow Stimulation and Lung Emphysema BC Lung Association

VanEeden, Stephan 52,234.00 The Systemic Inflammatory Response Induced by Air Pollution American Lung Association- Career Investigator Award

$73,234.00

Walley, Keith 26,769.00 Oxygen Extraction by Peripheral Tissues: Effect of Sepsis CIHR

Walley, Keith 98,948.00 Mechanisms of Myocardial Dysfunction During Sepsis Heart & Stroke Foundation

Walley, Keith 77,967.00 The Heart in Sepsis: Role of Leukocytes CIHR

Walley, Keith 29,686.00 Resuscitation of Early Septic Shock Using Albumin Plasma Protein Therapeutics Assoc.

Walley, Keith 90,000.00 Albumin in Endotoxemic Shock in Rats BayerRussell, James

$323,370.00

Wilcox, Pearce 30,000.00 The Effect of Alendronate on Markers of Bone Turnover and Bone Mineral BC Lung AssociationKendler Density in Osteopenic /Osteoporotic CF PatientsLevy, R.

$30,000.00

Yang, Decheng 73,892.00 Mechanisms of Tissue Tropism of Coxsachievirus B3: Molecular Basis for CIHRGene Therapy

Yang, Decheng 64,000.00 Viral Myocarditis: Functional Analysis of Differentially Expressed Genes in Heart & Stroke FoundationCoxsackievirus B3-Infected Mouse

Yang, Decheng 71,256.00 Functional Analysis of Three Differentially Expressed Genes in the Coxsackievirus CIHRB3-Infected Heart of Transgenic Mouse Models

Yang, Decheng 2,106.00 Mechanisms of Tissue Tropism of Coxsackievirus B3: Molecular Basis for Heart & Stroke FoundationGene Therapy

$211,254.00

Total $9,527,388.71

P R O J E C T C O O R D I N A T I O N : M E L A N I E H A N S O N , i C A P T U R E C O N C E P T A N D D E S I G N : S I G N A L S D E S I G N G R O U P W R I T I N G A N D

E D I T I N G : R O B Y N S U S S E L ( S I G N A L S ) A N D M E L A N I E H A N S O N ( i C A P T U R E ) P H O T O G R A P H Y : A L E X W A T E R H O U S E - H A Y W A R D

( D I R E C T O R S & G R O U P P H O T O ) S P E C I A L T H A N K S T O : J A N E T W I L S O N - M C M A N U S , W E N D Y C U N N I N G H A M , S H E M I M M A N J I ,

A N N E M C L A U G H L I N , A N D A L L M E M B E R S O F T H E i C A P T U R E T E A M W H O A G R E E D T O B E P H O T O G R A P H E D F O R T H I S P R O J E C T .

i C A P T U R 4 E

Imaging, Cell Analysis and Phenotyping Toward Understanding

Reparative, Responsive, Remodeling and Recombinant Events

To reach us directly, please contact:

The iCAPTUR4E Centre / MRL

B292– 1081 Burrard St.Vancouver, BC V6Z 1Y6

Tel: 604.806.8346Fax: 604.806.8351

info@mrl.ubc.cawww.icapture.ca

UBC Development Office6253 NW Marine DriveVancouver, BC V6T 1Z1

Tel: 604.682.8900Toll-Free: 1.877.717.GIVEFax: 604.822.8151

www.supporting.ubc.ca

For more information about supporting the iCAPTUR4E / MRL, please contact:

St. Paul's Hospital FoundationB164–1081 Burrard StreetVancouver, BC V6Z 1Y6

Tel: 604.682.8206Toll-Free: 1.800.720.2983 (BC only)Fax: 604.806.8326

www.helpstpauls.com